CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
ALT-803 +1 morebiological
Likely dose
ALT-803 20 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02523469
NCT02523469Phase 2Completed
CompareCT.gov

A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer

Medical University of South Carolina·interventional·Posted Aug 14, 2015·Updated Feb 17, 2026

In Brief

A Phase 2 clinical trial evaluating ALT-803 and Nivolumab for Non-small Cell Lung Cancer. Completed, enrolled 67 participants across 4 sites.

Detailed Summary

The purpose of the study is to define the safety and tolerability of this drug combination. The study will also define the response rate of patients with advanced and unresectable NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
CollaboratorsAltor BioScience

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 14, 2015
Enrollment StartJan 8, 2016
Primary CompletionFeb 24, 2023
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 10.9 years ago

Interventions

ALT-803biological

ALT-803 administered IV at doses per arm (6, 10, 15, 20 µg/kg)

Nivolumabbiological

Nivolumab administered IV at 3 mg/kg per protocol